Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIIb open-label single-arm study of pasireotide in acromegaly
2014-002630-31Phase 3Completed
- Sponsor
- Novartis
- Start
- Dec 2014
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of pasireotide LAR in acromegaly, sponsored by Novartis. Primary endpoint: Biochemical control of acromegaly. Started Dec 2014; status: completed.
02
Drugs
pasireotide LAR
03
Conditions
acromegaly
Beyond the preview
Go deeper on 2014-002630-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002630-31.